Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 8/20 | 0.80 |
| ▸ | P2RY2 | P41231 | 12/20 | 0.78 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.78 |
| ▸ | P2RY14 | Q15391 | 7/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL285071 | 0.91 | P2RY6 (0.83) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL157645 | 0.91 | P2RY6 (0.83) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL2056916 | 0.91 | P2RY6 (0.83) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL2683846 | 0.91 | P2RY6 (0.83) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL4071893 | 0.91 | P2RY6 (0.83) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL4166158 | 0.91 | P2RY6 (0.83) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL2056922 | 0.91 | P2RY6 (0.83) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL2056709 | 0.91 | P2RY6 (0.83) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL157644 | 0.91 | P2RY6 (0.83) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL30679287 | 0.91 | P2RY6 (0.83) | P2RY6P2RY2P2RY4P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091050-A1 | ADVANTAGEOUS ANTI-HCV COMBINATION THERAPY | Atea Pharmaceuticals, Inc. (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4667053-A2 | BETA-D-2'-DEOXY-2'ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | ATEA Pharmaceuticals, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12458656-B2 | Advantageous anti-HCV combination therapy | Atea Pharmaceuticals, Inc. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250281520-A1 | ADVANTAGEOUS ANTI-HCV COMBINATION THERAPY | Atea Pharmaceuticals, Inc. (US) | 2025-09-11 | — | — | US | disclosed |
| EP-3265102-B1 | BETA-D-2'-DEOXY-2'ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | ATEA PHARMACEUTICALS INC (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20250243235-A1 | Beta-D-2'-DEOXY-2'-alpha-FLUORO-2'-Beta-C-SUBSTITUTED-2-MODIFIED-N6- SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2025-07-31 | — | — | US | disclosed |
| US-20250109163-A1 | NUCLEOTIDE HEMI-SULFATE SALT FOR THE TREATMENT OF HEPATITIS C VIRUS | Atea Pharmaceuticals, Inc. (US) | 2025-04-03 | — | — | US | disclosed |
| EP-3577124-B1 | NUCLEOTIDE HEMI-SULFATE SALT FOR THE TREATMENT OF HEPATITIS C VIRUS | ATEA PHARMACEUTICALS INC (US) | 2024-12-11 | — | — | EP | disclosed |
| EP-4450129-A2 | NUCLEOTIDE HEMI-SULFATE SALT FOR THE TREATMENT OF HEPATITIS C VIRUS | ATEA Pharmaceuticals, Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| US-12084473-B2 | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (US) | 2024-09-10 | — | — | US | disclosed |
| WO-2018013937-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-4'-FLUORO-N6-SUBSTITUTED-6-AMINO-2-SUBSTITUTED PURINE NUCLEOTIDES FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION | Atea Pharmaceuticals, Inc. (US) | 2018-01-18 | — | — | WO | disclosed |
| EP-3265102-A1 | BETA-D-2'-DEOXY-2'ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | ATEA Pharmaceuticals, Inc. (US) | 2018-01-10 | — | — | EP | disclosed |
| CN-107427530-A | β -D-2 ' -deoxy-2 ' α -fluoro-2 ' - β -C-substituted-2-modified-N for HCV treatment6-substituted purine nucleotides | 阿堤亚制药公司 | 2017-12-01 | — | — | CN | disclosed |
| US-9828410-B2 | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (US) | 2017-11-28 | — | — | US | disclosed |
| CN-107074899-A | Improved flaorination process | 桑多斯股份公司 | 2017-08-18 | — | — | CN | disclosed |
| WO-2016144918-A1 | β-D-2'-DEOXY-2'α-FLUORO-2'-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2016-09-15 | — | — | WO | disclosed |
| US-20160257706-A1 | Beta-D-2'-DEOXY-2'-alpha-FLUORO-2'-beta-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2016-09-08 | — | — | US | disclosed |
| WO-2016014527-A2 | STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
| US-20160016986-A1 | STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT | ACHILLION PHARMACEUTICALS, INC. | 2016-01-21 | — | — | US | disclosed |
| JP-2003252894-A | METHOD OF PRODUCTION FOR URIDINE-5'-DIPHOSPHATE OLIGOSACCHARIDE | NOGUCHI INST | 2003-09-10 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016986-A1 | STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT | NUDT1, DUT, ADAR | P2RY6 271/4885P2RY2 315/4885P2RY4 249/4885 |
| US-20250109163-A1 | NUCLEOTIDE HEMI-SULFATE SALT FOR THE TREATMENT OF HEPATITIS C VIRUS | HAVCR2, HCCS, SLC10A1 | P2RY6 2493/4885P2RY2 3315/4885P2RY4 2658/4885 |
| US-12084473-B2 | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | NSUN2, PNP, NUDT1 | P2RY6 71/4885P2RY2 50/4885P2RY4 72/4885 |
| US-12458656-B2 | Advantageous anti-HCV combination therapy | HAVCR2, SLC10A1, EIF2AK2 | P2RY6 3717/4885P2RY2 3823/4885P2RY4 4047/4885 |
| US-20250243235-A1 | Beta-D-2'-DEOXY-2'-alpha-FLUORO-2'-Beta-C-SUBSTITUTED-2-MODIFIED-N6- SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | NSUN2, NUDT1, DCTD | P2RY6 149/4885P2RY2 84/4885P2RY4 136/4885 |
| US-20250281520-A1 | ADVANTAGEOUS ANTI-HCV COMBINATION THERAPY | HAVCR2, SLC10A1, EIF2AK2 | P2RY6 3717/4885P2RY2 3823/4885P2RY4 4047/4885 |
| US-20260091050-A1 | ADVANTAGEOUS ANTI-HCV COMBINATION THERAPY | SLC10A1, SLC10A2, STAT3 | P2RY6 2210/4885P2RY2 1201/4885P2RY4 1861/4885 |
| US-20160257706-A1 | Beta-D-2'-DEOXY-2'-alpha-FLUORO-2'-beta-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | NSUN2, NUDT1, DCTD | P2RY6 149/4885P2RY2 84/4885P2RY4 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.